Lincoln Pharmaceuticals Ltd Q1FY21 consolidated PAT at Rs. 15.26 crore

LINCOLN PHARMACEUTICALS LTD. has reported financial results for the period ended June 30, 2020.

Financial Results (Q1 FY 2020-21) - QoQ Comparison

The company has reported total income of Rs.105.59 crores during the period ended June 30, 2020 as compared to Rs.82.65 crores during the period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.15.25 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.8.94 crores for the period ended March 31, 2020.

The company has reported EPS of Rs.7.63 for the period ended June 30, 2020 as compared to Rs.4.47 for the period ended March 31, 2020.

Financials	Q1 FY2020-21	Q4 FY19-20	% Change
Total Income	₹ 105.59 crs	₹ 82.65 crs	27.76%
Net Profit	₹ 15.25 crs	₹ 8.94 crs	70.58%
EPS	₹ 7.63	₹ 4.47	70.69%

Financial Results (Q1 FY 2020-21) - YoY Comparison

The company has reported total income of Rs.105.59 crores during the period ended June 30, 2020 as compared to Rs.98.10 crores during the period ended June 30, 2019.

The company has posted net profit / (loss) of Rs.15.25 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.12.67 crores for the period ended June 30, 2019.

The company has reported EPS of Rs.7.63 for the period ended June 30, 2020 as compared to Rs.6.33 for the period ended June 30, 2019.

Financials	Q1 FY2020-21	Q1 FY2019-20	% Change
Total Income	₹ 105.59 crs	₹ 98.10 crs	7.64%
Net Profit	₹ 15.25 crs	₹ 12.67 crs	20.36%
EPS	₹ 7.63	₹ 6.33	20.54%

Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "We are pleased to announce that Lincoln Pharma has become a zero net-debt company by paying all its outstanding debt. Despite a challenging economic and business environment due to COVID 19, company has delivered a robust financial performance quarter over quarter maintaining healthy growth in revenue, profitability and expects to continue the growth momentum in the coming years. Exports sales (FOB) for the Ql increased 40.00% to Rs. 82.08 crore and expected to get further boost post EU approval. Strategic growth initiatives, strong performance in the domestic and international markets, EU approval, new product approvals, better margin products along with operational efficiency are likely to contribute healthy growth and maximise value for all stakeholders in the near to medium term."

Shares of LINCOLN PHARMACEUTICALS LTD. was last trading in BSE at Rs.237.8 as compared to the previous close of Rs. 231.7. The total number of shares traded during the day was 93154 in over 3481 trades.

The stock hit an intraday high of Rs. 239.35 and intraday low of 228.4. The net turnover during the day was Rs. 21888029.

Source : Equity Bulls

Keywords